Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EWTX NASDAQ:KNSA NASDAQ:SVRA NASDAQ:TNGX On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWTXEdgewise Therapeutics$41.51+1.4%$34.79$12.30▼$43.93$4.46B0.271.18 million shs146,950 shsKNSAKiniksa Pharmaceuticals International$64.28+3.0%$52.51$26.27▼$64.45$4.94B0.12720,033 shs299,926 shsSVRASavara$6.03+0.0%$5.26$1.98▼$7.01$1.24B0.261.60 million shs273,613 shsTNGXTango Therapeutics$33.18+1.9%$25.33$4.80▼$34.39$4.80B1.193.77 million shs1.45 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWTXEdgewise Therapeutics-1.30%+12.11%+19.79%+29.90%+210.71%KNSAKiniksa Pharmaceuticals International+5.42%+9.24%+29.00%+29.62%+122.57%SVRASavara+2.20%+5.98%+15.96%+10.44%+172.85%TNGXTango Therapeutics+3.46%+14.25%+48.13%+55.45%+549.90%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEWTXEdgewise Therapeutics$41.51+1.4%$34.79$12.30▼$43.93$4.46B0.271.18 million shs146,950 shsKNSAKiniksa Pharmaceuticals International$64.28+3.0%$52.51$26.27▼$64.45$4.94B0.12720,033 shs299,926 shsSVRASavara$6.03+0.0%$5.26$1.98▼$7.01$1.24B0.261.60 million shs273,613 shsTNGXTango Therapeutics$33.18+1.9%$25.33$4.80▼$34.39$4.80B1.193.77 million shs1.45 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2026 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEWTXEdgewise Therapeutics-1.30%+12.11%+19.79%+29.90%+210.71%KNSAKiniksa Pharmaceuticals International+5.42%+9.24%+29.00%+29.62%+122.57%SVRASavara+2.20%+5.98%+15.96%+10.44%+172.85%TNGXTango Therapeutics+3.46%+14.25%+48.13%+55.45%+549.90%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEWTXEdgewise Therapeutics 2.78Moderate Buy$47.3013.89% UpsideKNSAKiniksa Pharmaceuticals International 3.00Buy$62.71-2.65% DownsideSVRASavara 2.88Moderate Buy$10.1467.51% UpsideTNGXTango Therapeutics 2.73Moderate Buy$41.5025.16% UpsideCurrent Analyst Ratings BreakdownLatest SVRA, KNSA, TNGX, and EWTX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/29/2026KNSAKiniksa Pharmaceuticals International WedbushSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$59.00 ➝ $72.006/29/2026TNGXTango Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$42.00 ➝ $46.006/25/2026TNGXTango Therapeutics Jefferies Financial GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Buy$27.00 ➝ $60.006/25/2026TNGXTango Therapeutics Raymond James FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold6/23/2026KNSAKiniksa Pharmaceuticals International Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy (B-) ➝ Hold (C+)6/17/2026EWTXEdgewise Therapeutics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$48.00 ➝ $59.006/17/2026EWTXEdgewise Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$20.00 ➝ $32.006/17/2026KNSAKiniksa Pharmaceuticals International Zacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy6/16/2026EWTXEdgewise Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$52.006/16/2026EWTXEdgewise Therapeutics HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$45.006/12/2026TNGXTango Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)(Data available from 6/30/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEWTXEdgewise TherapeuticsN/AN/AN/AN/A$4.93 per shareN/AKNSAKiniksa Pharmaceuticals International$754.05M6.57$0.86 per share74.58$7.44 per share8.66SVRASavaraN/AN/AN/AN/A$1.00 per shareN/ATNGXTango Therapeutics$62.38M76.89N/AN/A$2.57 per share12.90Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEWTXEdgewise Therapeutics-$167.79M-$1.66N/AN/AN/AN/A-32.55%-31.04%8/6/2026 (Estimated)KNSAKiniksa Pharmaceuticals International$59.01M$0.9071.5237.90N/A9.69%13.26%9.86%7/28/2026 (Estimated)SVRASavara-$118.84M-$0.56N/AN/AN/AN/A-87.19%-66.42%8/12/2026 (Estimated)TNGXTango Therapeutics-$101.59M-$0.83N/AN/AN/A-151.15%-41.54%-33.44%8/4/2026 (Estimated)Latest SVRA, KNSA, TNGX, and EWTX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails7/28/2026Q2 2026KNSAKiniksa Pharmaceuticals International$0.30N/AN/AN/A$226.49 millionN/A5/13/2026Q1 2026TNGXTango Therapeutics-$0.32-$0.32N/A-$0.32$0.58 millionN/A5/12/2026Q1 2026SVRASavara-$0.14-$0.15-$0.01-$0.15$0.50 millionN/A5/7/2026Q1 2026EWTXEdgewise Therapeutics-$0.50-$0.46+$0.04-$0.46N/AN/A4/28/2026Q1 2026KNSAKiniksa Pharmaceuticals International$0.18$0.27+$0.09$0.27$206.11 million$214.27 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthEWTXEdgewise TherapeuticsN/AN/AN/AN/AN/AKNSAKiniksa Pharmaceuticals InternationalN/AN/AN/AN/AN/ASVRASavaraN/AN/AN/AN/AN/ATNGXTango TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEWTXEdgewise TherapeuticsN/A22.6122.61KNSAKiniksa Pharmaceuticals InternationalN/A3.793.33SVRASavara0.1713.4713.47TNGXTango TherapeuticsN/A27.3827.38Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEWTXEdgewise TherapeuticsN/AKNSAKiniksa Pharmaceuticals International53.95%SVRASavara87.93%TNGXTango Therapeutics78.99%Insider OwnershipCompanyInsider OwnershipEWTXEdgewise Therapeutics21.30%KNSAKiniksa Pharmaceuticals International51.98%SVRASavara5.30%TNGXTango Therapeutics6.50%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEWTXEdgewise Therapeutics60107.59 million84.68 millionOptionableKNSAKiniksa Pharmaceuticals International22076.94 million36.95 millionOptionableSVRASavara20204.93 million194.07 millionOptionableTNGXTango Therapeutics90144.65 million135.25 millionOptionableSVRA, KNSA, TNGX, and EWTX HeadlinesRecent News About These CompaniesTango Therapeutics Appoints Robert Azelby to Board of DirectorsJune 22, 2026 | globenewswire.comTango Therapeutics (NASDAQ:TNGX) Shares Down 8.6% - Here's What HappenedJune 20, 2026 | americanbankingnews.comIs Tango Therapeutics (TNGX) Price Justified After Its 7x Surge In One YearJune 10, 2026 | finance.yahoo.comTango Therapeutics Announces Major Underwritten Equity OfferingJune 10, 2026 | tipranks.comTango Therapeutics Announces Pricing of $600 Million Underwritten Offering of Common Stock and Pre-Funded WarrantsJune 9, 2026 | quiverquant.comQTango Therapeutics Announces Pricing of $600 Million Upsized Public OfferingJune 9, 2026 | globenewswire.comTango Therapeutics: Combo Data With Revolution's RAS Inhibitor Whets Risk AppetiteJune 9, 2026 | seekingalpha.comTango Therapeutics (TNGX) stock soars on pancreatic cancer trial resultsJune 9, 2026 | msn.comTNGX Stock Jumps 53% on Early Pancreatic Cancer Study ResultsJune 9, 2026 | zacks.comTango shares surge on early pancreatic cancer combination dataJune 9, 2026 | thepharmaletter.comTTango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer TranscriptJune 8, 2026 | seekingalpha.comTango Therapeutics stock soars on promising pancreatic cancer dataJune 8, 2026 | invezz.comITango Therapeutics Announces Proposed $500 Million Public OfferingJune 8, 2026 | globenewswire.comTango Therapeutics, Inc. (TNGX) Discusses Promising Clinical Results for Vopimetostat and Pan-RAS Inhibitor Combination in MTAP-Deleted Pancreatic Cancer - SlideshowJune 8, 2026 | seekingalpha.comTango Therapeutics stock soars on promising pancreatic cancer dataJune 8, 2026 | invezz.comIStock Movers: Intel, Tango Therapeutics, StrategyJune 8, 2026 | bloomberg.comTNGX stock hits all-time high – Wolfe Research calls Tango Therapeutic’s pancreatic cancer trial data ‘groundbreaking’June 8, 2026 | msn.comTango Therapeutics Stock Soars 42% After 'Unprecedented' Data on Pancreatic Cancer TreatmentJune 8, 2026 | barrons.comTango skyrockets 47% on eye-popping pancreatic cancer resultsJune 8, 2026 | msn.comTango Therapeutics' pancreatic cancer drug combo shows promise in studyJune 8, 2026 | reuters.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeSVRA, KNSA, TNGX, and EWTX Company DescriptionsEdgewise Therapeutics NASDAQ:EWTX$41.51 +0.59 (+1.43%) As of 11:41 AM Eastern This is a fair market value price provided by Massive. Learn more.Edgewise Therapeutics, Inc., a biopharmaceutical company, discovers, develops, and commercializes therapies for the treatment of muscle disorders. Its lead product candidate, EDG-5506, an orally administered small molecule that is in Phase II clinical trials, designed to address the root cause of dystrophinopathies including Duchenne muscular dystrophy and Becker muscular dystrophy. The company develops EDG-7500, a small molecule for the treatment of hypertrophic cardiomyopathy and other severe cardiac disorders that is in Phase I clinical trials. In addition, it develops a pipeline of precision medicine product candidates that target key muscle proteins and modulators to address genetically defined muscle disorders. Edgewise Therapeutics, Inc. was incorporated in 2017 and is headquartered in Boulder, Colorado.Kiniksa Pharmaceuticals International NASDAQ:KNSA$64.28 +1.87 (+3.00%) As of 11:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, that is in Phase 2b clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. The company was incorporated in 2015 and is based in Hamilton, Bermuda.Savara NASDAQ:SVRA$6.03 +0.00 (+0.03%) As of 11:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Savara Inc., formerly Mast Therapeutics, Inc., is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients. Molgradex is an inhaled formulation of recombinant human granulocyte-macrophage colony-stimulating factor. It is developing Molgradex for the treatment of autoimmune pulmonary alveolar proteinosis, a rare lung disease. AIR001 is a sodium nitrite solution for inhalation via nebulization. AIR001 is in Phase II clinical development for the treatment of heart failure with preserved ejection fraction, also known as diastolic heart failure or heart failure with preserved systolic function.Tango Therapeutics NASDAQ:TNGX$33.18 +0.62 (+1.91%) As of 11:42 AM Eastern This is a fair market value price provided by Massive. Learn more.Tango Therapeutics, Inc., a biotechnology company, discovers and develops drugs for the treatment of cancer. Its lead program is TNG908, a synthetic lethal small molecule inhibitor of protein arginine methyltransferase 5 that is being developed as a treatment for cancers with methylthioadenosine phosphorylase deletions. The company develops TNG462, an oral small molecule methylthioadenosine-cooperative inhibitor for the treatment for cancers with methylthioadenosine phosphorylase deletions; TNG260, a co-repressor of repressor element-1 silencing transcription -selective inhibitor; TNG348, an ubiquitin-specific protease 1 inhibitor to treat patients with BRCA1 or BRCA2-mutant cancers; and Target 3 for STK11-mutant cancers. It has a strategic collaboration with Gilead Sciences, Inc. for the discovery, development, and commercialization of a pipeline of therapies for patients with cancer. Tango Therapeutics, Inc. was founded in 2017 and is headquartered in Boston, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas SpaceX Achieves Escape Velocity With Nasdaq Fast-Track 3 Top Financial Institutions Announce Over $70 Billion in Share Repurchases Rezolve AI Stock Has a Short-Squeeze Setup, But Execution Comes First The AI Boom Has a Second Act—And It's Playing Out in Optics Gold’s 2026 Rally Has Cracked—Is It Time to Buy the Pullback? 5 Tech Stocks to Buy on the July Pullback Is OpenAI’s IPO Delay a Warning for AI Investors? onsemi: What the Market Gets Wrong, You Can Get Right Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
